Bacterial brain

Why Sequoia is backing Cortexyme’s Alzheimer’s hypothesis by leading $76M round

Preclinical data backing Cortexyme Inc.’s hypothesis that a bacterial pathogen drives Alzheimer’s disease, combined with clinical safety data, convinced Sequoia Capital to lead the company’s $76 million series B.

The round closed on May 31 with participation from fellow

Read the full 385 word article

User Sign In